Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00856492
What this trial is testing

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 215
Early research (Phase 1)Study completedNCT04647487
What this trial is testing

LY3484356 in Women With Breast Cancer Before Having Surgery

Who this might be right for
Breast Cancer
Eli Lilly and Company 87
Testing effectiveness (Phase 2)Study completedNCT02860000
What this trial is testing

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Who this might be right for
Estrogen Receptor StatusHER2/Neu NegativeInvasive Breast Carcinoma+6 more
Mayo Clinic 96
Large-scale testing (Phase 3)Looking for participantsNCT04263298
What this trial is testing

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Herui Yao 210
Not applicableStudy completedNCT04524728
What this trial is testing

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Who this might be right for
BreastNeoplasm MalignantFemale
Istituti Clinici Scientifici Maugeri SpA 191
Testing effectiveness (Phase 2)Looking for participantsNCT05824975
What this trial is testing

Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
GI Innovation, Inc. 358
Testing effectiveness (Phase 2)Ended earlyNCT02826512
What this trial is testing

A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 9
Testing effectiveness (Phase 2)Study completedNCT05520723
What this trial is testing

Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED

Who this might be right for
Triple Negative Breast CancerBreast CancerAdvanced HR+/HER2- Breast Cancer
MedSIR 50
Testing effectiveness (Phase 2)Looking for participantsNCT07396324
What this trial is testing

Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

Who this might be right for
HR-positive/HER2-negative Breast Cancer
RenJi Hospital 55
Testing effectiveness (Phase 2)Active Not RecruitingNCT05296746
What this trial is testing

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Who this might be right for
Breast Cancer Stage II
SOLTI Breast Cancer Research Group 1,100
Large-scale testing (Phase 3)Ended earlyNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Testing effectiveness (Phase 2)Looking for participantsNCT06167694
What this trial is testing

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Who this might be right for
Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd. 146
Testing effectiveness (Phase 2)Study completedNCT01575522
What this trial is testing

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+3 more
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)UnknownNCT05198856
What this trial is testing

Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC

Who this might be right for
Gastric Cancer Metastatic to Liver
Qilu Hospital of Shandong University 106
Testing effectiveness (Phase 2)Looking for participantsNCT06450873
What this trial is testing

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

Who this might be right for
Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
Mayo Clinic 40
Testing effectiveness (Phase 2)Looking for participantsNCT07193394
What this trial is testing

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer ( HER2 Negative)Unresectable Breast Cancer
Institut Curie 20
Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Early research (Phase 1)Looking for participantsNCT05304962
What this trial is testing

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Regor Pharmaceuticals Inc. 64
Testing effectiveness (Phase 2)Looking for participantsNCT07427394
What this trial is testing

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 24
Next Page